David Wojciechowski

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Effect of ciprofloxacin combined with sulfamethoxazole-trimethoprim prophylaxis on the incidence of urinary tract infections after kidney transplantation
    David Wojciechowski
    Kidney Transplant Service, Division of Nephrology, Department of Medicine, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
    Transplantation 96:400-5. 2013
  2. ncbi request reprint Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year
    David Wojciechowski
    Kidney Transplant Service, Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Transplantation 94:1117-23. 2012
  3. doi request reprint Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation
    David Wojciechowski
    University of California, San Francisco, Kidney Transplant Service, CA 94143 0780, United States
    Semin Immunol 23:157-64. 2011
  4. ncbi request reprint Tofacitinib in kidney transplantation
    David Wojciechowski
    University of California, Kidney Transplant Service, San Francisco, CA 94143 0780, USA
    Expert Opin Investig Drugs 22:1193-9. 2013
  5. doi request reprint Belatacept in kidney transplantation
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 17:640-7. 2012
  6. ncbi request reprint How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, California, USA
    Curr Opin Organ Transplant 15:697-702. 2010
  7. doi request reprint Targeting JAK3 in kidney transplantation: current status and future options
    David Wojciechowski
    University of California, San Francisco, Kidney Transplant Service, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 16:614-9. 2011
  8. pmc Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, CA, USA
    Biologics 6:385-93. 2012

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Effect of ciprofloxacin combined with sulfamethoxazole-trimethoprim prophylaxis on the incidence of urinary tract infections after kidney transplantation
    David Wojciechowski
    Kidney Transplant Service, Division of Nephrology, Department of Medicine, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
    Transplantation 96:400-5. 2013
    ..Urinary tract infections (UTIs) are common after kidney transplantation, with limited data to guide antibiotic prophylaxis...
  2. ncbi request reprint Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year
    David Wojciechowski
    Kidney Transplant Service, Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Transplantation 94:1117-23. 2012
    ..A strategy of fluoroquinolone prophylaxis directed specifically against BKV has not been formally tested against a control group in kidney transplant recipients...
  3. doi request reprint Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation
    David Wojciechowski
    University of California, San Francisco, Kidney Transplant Service, CA 94143 0780, United States
    Semin Immunol 23:157-64. 2011
    ....
  4. ncbi request reprint Tofacitinib in kidney transplantation
    David Wojciechowski
    University of California, Kidney Transplant Service, San Francisco, CA 94143 0780, USA
    Expert Opin Investig Drugs 22:1193-9. 2013
    ..This review will discuss the mechanism of action and important kidney transplant clinical trial data for the small molecule Janus kinase (JAK) 3 inhibitor tofacitinib , formerly known as CP-690,550 and tasocitinib...
  5. doi request reprint Belatacept in kidney transplantation
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 17:640-7. 2012
    ..This review will discuss the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen...
  6. ncbi request reprint How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, California, USA
    Curr Opin Organ Transplant 15:697-702. 2010
    ..The purpose of this review is to discuss the use of belatacept as part of an immunosuppression regimen in renal transplant recipients to avoid the renal and nonrenal toxicities associated with calcineurin inhibitors (CNIs)...
  7. doi request reprint Targeting JAK3 in kidney transplantation: current status and future options
    David Wojciechowski
    University of California, San Francisco, Kidney Transplant Service, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 16:614-9. 2011
    ..This review will discuss the mechanism of action and important clinical trial data in renal transplantation for the small molecule Janus kinase (JAK) 3 inhibitor tofacitinib, formerly known as CP-690,550 and tasocitinib...
  8. pmc Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, CA, USA
    Biologics 6:385-93. 2012
    ..Therefore, belatacept can be recommended for use in Epstein-Barr virus antibody-positive recipients...